|
|
Article: Cytokine PharmaSciences Licenses Anti-MIF Technology To Baxter Healthcare Corporation.
- Article from:
- PR Newswire
- Article date:
- March 13, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
KING OF PRUSSIA, Pa. -- KING OF PRUSSIA, Pa., March 13 /PRNewswire/ -- Cytokine PharmaSciences, Inc. has signed an exclusive license with Baxter Healthcare Corporation for rights to Cytokine's anti-macrophage migration inhibitory factor (MIF) antibody technology. The agreement involves an up-front payment, milestones and royalties in return for an exclusive license to all developed indications. Specific terms were not disclosed. Baxter will be responsible for development and is preparing to begin a complete set of preclinical experiments in anticipation of entering the clinic.
MIF is a cytokine involved in immune, infectious and malignant disorders. Discovered ...